Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG1837 in Healthy Subjects

Trial Profile

Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG1837 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLPG 1837 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV
  • Most Recent Events

    • 09 Oct 2015 According to Galapagos NV media release, results were presented at the North American Cystic Fibrosis Conference (NACFC) 2015.
    • 09 Oct 2015 Results published in a Galapagos NV media release.
    • 08 Oct 2015 Results will be presented at the North American Cystic Fibrosis Conference (NACFC) 2015, according to Galapagos NV media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top